Helia Biomonitoring is developing an innovative technology for continuous biomolecular monitoring. The technology has the potential to continuously measure many substances (small molecules, hormones, drugs, peptides, proteins, nucleic acids) and can cover a wide range of concentrations (picomolar to millimolar). Potential applications include the continuous monitoring of patients in order to provide therapy feedback and prevent severe conditions and the continuous monitoring of industrial and environmental processes.
The technology called BPM, Biosensing based on Particle Mobility, is based on the tracking of the motion of particles that are molecularly tethered to a surface, where the motion reveals reversible biochemical interactions with single-molecule resolution. Hundreds of particles are simultaneously recorded by optical imaging, giving access to data with high statistics and allowing biosensing with high sensitivity and precision. We are now developing biomolecular assays and we are engineering an automated BPM prototype system for testing in practical applications.
2014 | WO2016075226 | US granted
2014 | WO2016075229 | EU granted, US granted
2014 | WO2016096901 | EU granted, US granted, CN granted, JP granted
2016 | WO2018122401 | EU granted, US granted
2017 | WO2018158469 | US granted
2020 | WO2022039594
2021 | WO2023022589